Ran Nussbaum - Apr 7, 2020 Form 3/A - Amendment Insider Report for Keros Therapeutics, Inc. (KROS)

Role: Director, 10%+ Owner
Signature: /s/ Keith Regnante, Attorney-in-Fact
Stock symbol: KROS
Transactions as of: Apr 7, 2020
Transactions value $: $0
Form type: 3/A - Amendment
Date filed: 11/30/2022, 03:36 PM
Date Of Original Report: Apr 7, 2020
Next filing: Jun 9, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	KROS	Call Options (obligation to sell)							Apr 7, 2020	Common Stock	3.54K	$0.00	See footnote	F1, F2, F3
holding	KROS	Call Options (obligation to sell)							Apr 7, 2020	Common Stock	1.72K	$0.00	See footnote	F1, F2, F4
holding	KROS	Call Options (obligation to sell)							Apr 7, 2020	Common Stock	1.91K	$0.00	See footnote	F1, F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This security was inadvertently omitted from the Original Form 3.
F2	Fully vested and exercisable.
F3	The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
F4	The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
F5	The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.